Antifungal Drugs Market: By Drug Class, By Route of Administration, By Therapeutic Indications, By Distribution Channel and Region Forecast 2019-2030
Antifungal Drugs Market size was valued at US$ 15,812.5 million in 2023 and is expected to grow at a CAGR of 4.3% from 2024 to 2030. The global market provides a detailed overview that can be segmented by drug type, route of administration, Therapeutic indication, and distribution channel. By drug type, the market growth has been segmented into Azoles, Polyenes, Echinocandins, Allylamines, and Others.
The Azoles segment is likely to be the largest and fastest-growing segment in terms of drug type. Azoles are used to treat candidemia, blastomycosis, ocular fungal infections, and systemic candidiasis. It helps in fungistatic activities by hindering fungal enzymes. Azoles are also utilized in the treatment of systemic fungal infections, divided into imidazoles and triazoles. They provide an extensive spectrum of activity along with improved safety levels. Triazoles have less severe effects, fewer serious drug interactions, and enhanced distribution and absorption properties.
The above-mentioned advantages of the use of azoles are attributed to the market share. Based on the Route of administration, the market is segmented into Oral, Parenteral, and Topical. Among these, the Topical route of administration segment is expected to have a significantly growing market during the forecast period. Based on the Therapeutic indication, the market is segmented into Aspergillosis, Candidiasis, Dermatophytosis, and Others.
The Candidiasis segment is expected to have a significant share in 2021. Candidiasis is the most frequently happening systemic fungal infection. It is a yeast infection by the genus Candida. Its process to cure has changed over time. Some of the variations comprise suitable usage of broad-spectrum azoles and echinocandins for the treatment of candidemia, invasive candidiasis, and mucosal candidiasis. Based on the distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies, Drug stores, and Online pharmacies.
Study Period
2024-2030Base Year
2023CAGR
4.3%Largest Market
North AmericaFastest Growing Market
Asia pacific
The growing incidences of nosocomial and fungal infections are anticipated to propel the market growth over the forecast years. Moreover, the growing healthcare expenditure, which helps in refining its infrastructure, is burgeoning the market growth over the forecast years.
North America holds the largest share in the antifungal drugs market followed by Europe and Asia-Pacific, owing to increasing patient awareness, R&D expenditure for development of new drugs, and increase in prevalence rate of fungal infections in U.S. (According to Centre for Disease Control and Prevention (CDC) approximately 46,000 new cases of candidiasis occur every year in U.S.)
Europe holds a major market share in the anti-fungal drugs market attributed to an increase in the prevalence rate of fungal infections in Europe and the development of antifungal biopharmaceuticals.
Asia Pacific accounts for significant growth owing to the burgeoning consumer base and development in the economies of China and India. Rising income per capita, increasing awareness about personal hygiene, and increase in healthcare expenditure might fuel the antifungal drugs market in the Asia-Pacific region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 15,812.5 million |
|
Market CAGR |
4.3% |
|
By Drug Class |
|
|
By Route of Administration |
|
|
By Therapeutic Indication |
|
|
By Distribution Channel |
|
Download Free Sample Report
The global antifungal drugs market size was valued at US$ 15,812.5 million in 2023 and is projected to grow at a CAGR of 4.3% from 2024 to 2030.
The anti-fungal drugs market key players are: Pfizer, Inc. (U.S.) Novartis AG (Switzerland) Sanofi (France) Merck & Co., Inc. (U.S.) Enzon Pharmaceuticals, Inc. (U.S.) Bayer AG (Germany) Astellas Pharma, Inc. (Japan) GlaxoSmithKline plc. (U.K.) Mylan N.V. (U.S.) Tecan Group (Switzerland) AureoGen Biosciences Inc. (U.S.)
The anti fungal drugs market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1. Executive Summary |
| 2. Global Anti-fungal Drugs Market Introduction |
| 2.1. Global Anti-fungal Drugs Market – Taxonomy |
| 2.2. Global Anti-fungal Drugs Market – Definitions |
| 2.2.1. Drug Class |
| 2.2.2. Route of Administration |
| 2.2.3. Therapeutic Indications |
| 2.2.4. Distribution Channel |
| 3. Global Anti-fungal Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Anti-fungal Drugs Market Dynamic Factors - Impact Analysis |
| 3.6. Global Anti-fungal Drugs Market – Competition Landscape |
| 3.7. Epidemiology |
| 4. Global Anti-fungal Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Anti-fungal Drugs Market, By Drug Class, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1. Azoles |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Polyenes |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Echinocandins |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Allylamines |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6. Global Anti-fungal Drugs Market Forecast, By Route of Administration, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Parenteral |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Topical |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Anti-fungal Drugs Market Forecast, By Therapeutic Indications, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1. Aspergillosis |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Candidiasis |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Dermatophytosis |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Others |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8. Global Anti-fungal Drugs Market Forecast (2019 - 2023 and 2024 - 2030) |
| 8.1. Retail Pharmacies |
| 8.1.1. Market Analysis (2019 - 2023 and 2024 - 2030) (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Hospital Pharmacies |
| 8.2.1. Market Analysis (2019 - 2023 and 2024 - 2030) (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Drug Stores |
| 8.3.1. Market Analysis (2019 - 2023 and 2024 - 2030) (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Online Pharmacies |
| 8.4.1. Market Analysis (2019 - 2023 and 2024 - 2030) (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 9. Global Anti-fungal Drugs Market Forecast by Region (2019 - 2023 and 2024 - 2030) |
| 9.1. North America |
| 9.1.1. Market Analysis (2019 - 2023 and 2024 - 2030) (Revenue, USD Mn) |
| 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis (2019 - 2023 and 2024 - 2030) (Revenue, USD Mn) |
| 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia-Pacific |
| 9.3.1. Market Analysis (2019 - 2023 and 2024 - 2030) (Revenue, USD Mn) |
| 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Latin America |
| 9.4.1. Market Analysis (2019 - 2023 and 2024 - 2030) (Revenue, USD Mn) |
| 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Middle East and Africa |
| 9.5.1. Market Analysis (2019 - 2023 and 2024 - 2030) (Revenue, USD Mn) |
| 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10. Global Anti-fungal Drugs Market - Opportunity Analysis Index |
| 10.1. By Drug Class, Route of Administration, Therapeutic Indications, Distribution Channel, and Region (2024 - 2030) |
| 11. North America Anti-fungal Drugs Market Analysis (2019 - 2023 and 2024 - 2030) |
| 11.1. Drug Class Analysis |
| 11.1.1. Azoles |
| 11.1.2. Polyenes |
| 11.1.3. Echinocandins |
| 11.1.4. Allylamines |
| 11.1.5. Others |
| 11.2. Route of Administration Analysis |
| 11.2.1. Oral |
| 11.2.2. Parenteral |
| 11.2.3. Topical |
| 11.3. Therapeutic Indications Analysis |
| 11.3.1. Aspergillosis |
| 11.3.2. Candidiasis |
| 11.3.3. Dermatophytosis |
| 11.3.4. Others |
| 11.4. Distribution Channel Analysis |
| 11.4.1. Retail Pharmacies |
| 11.4.2. Hospital Pharmacies |
| 11.4.3. Drug Stores |
| 11.4.4. Online Pharmacies |
| 11.5. Country Analysis |
| 11.5.1. U.S. |
| 11.5.2. Canada |
| 11.6. North America Anti-fungal Drugs Market - Opportunity Analysis Index |
| Continue this format for sections 12, 13, and 14 for Europe, Asia-Pacific, and Latin America, respectively. |
| 12. Europe Anti-fungal Drugs Market Analysis (2019 - 2023 and 2024 - 2030) |
| 12.1. Drug Class Analysis |
| 12.1.1. Azoles |
| 12.1.2. Polyenes |
| 12.1.3. Echinocandins |
| 12.1.4. Allylamines |
| 12.1.5. Others |
| 12.2. Route of Administration Analysis |
| 12.2.1. Oral |
| 12.2.2. Parenteral |
| 12.2.3. Topical |
| 12.3. Therapeutic Indications Analysis |
| 12.3.1. Aspergillosis |
| 12.3.2. Candidiasis |
| 12.3.3. Dermatophytosis |
| 12.3.4. Others |
| 12.4. Distribution Channel Analysis |
| 12.4.1. Retail Pharmacies |
| 12.4.2. Hospital Pharmacies |
| 12.4.3. Drug Stores |
| 12.4.4. Online Pharmacies |
| 12.5. Country Analysis |
| 12.5.1. Germany |
| 12.5.2. UK |
| 12.5.3. France |
| 12.5.4. Spain |
| 12.5.5. Italy |
| 12.5.6. Russia |
| 12.5.7. Poland |
| 12.5.8. Rest of Europe |
| 12.6. Europe Anti-fungal Drugs Market - Opportunity Analysis Index |
| 13. Asia-Pacific Anti-fungal Drugs Market Analysis (2019 - 2023 and 2024 - 2030) |
| 13.1. Drug Class Analysis |
| 13.1.1. Azoles |
| 13.1.2. Polyenes |
| 13.1.3. Echinocandins |
| 13.1.4. Allylamines |
| 13.1.5. Others |
| 13.2. Route of Administration Analysis |
| 13.2.1. Oral |
| 13.2.2. Parenteral |
| 13.2.3. Topical |
| 13.3. Therapeutic Indications Analysis |
| 13.3.1. Aspergillosis |
| 13.3.2. Candidiasis |
| 13.3.3. Dermatophytosis |
| 13.3.4. Others |
| 13.4. Distribution Channel Analysis |
| 13.4.1. Retail Pharmacies |
| 13.4.2. Hospital Pharmacies |
| 13.4.3. Drug Stores |
| 13.4.4. Online Pharmacies |
| 13.5. Country Analysis |
| 13.5.1. Japan |
| 13.5.2. China |
| 13.5.3. India |
| 13.5.4. ASEAN |
| 13.5.5. Australia & New Zealand |
| 13.5.6. Rest of Asia-Pacific |
| 13.6. Asia-Pacific Anti-fungal Drugs Market - Opportunity Analysis Index |
| 14. Latin America Anti-fungal Drugs Market Analysis (2012 - 2019 - 2023 and 2024 - 2030) |
| 14.1. Drug Class Analysis |
| 14.1.1. Azoles |
| 14.1.2. Polyenes |
| 14.1.3. Echinocandins |
| 14.1.4. Allylamines |
| 14.1.5. Others |
| 14.2. Route of Administration Analysis |
| 14.2.1. Oral |
| 14.2.2. Parenteral |
| 14.2.3. Topical |
| 14.3. Therapeutic Indications Analysis |
| 14.3.1. Aspergillosis |
| 14.3.2. Candidiasis |
| 14.3.3. Dermatophytosis |
| 14.3.4. Others |
| 14.4. Distribution Channel Analysis |
| 14.4.1. Retail Pharmacies |
| 14.4.2. Hospital Pharmacies |
| 14.4.3. Drug Stores |
| 14.4.4. Online Pharmacies |
| 14.5. Country Analysis |
| 14.5.1. Brazil |
| 14.5.2. Mexico |
| 14.5.3. Argentina |
| 14.5.4. Venezuela |
| 14.5.5. Rest of Latin America |
| 14.6. Latin America Anti-Fungal Drugs Market - Opportunity Analysis Index |
| 15. Competition Landscape |
| 15.1. Strategic Dashboard of Top Market Players |
| 15.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 15.2.1. Pfizer, Inc. (U.S.) |
| 15.2.2. Novartis AG (Switzerland) |
| 15.2.3. Sanofi (France) |
| 15.2.4. Merck & Co., Inc. (U.S.) |
| 15.2.5. Enzon Pharmaceuticals, Inc. (U.S.) |
| 15.2.6. Bayer AG (Germany) |
| 15.2.7. Astellas Pharma, Inc. (Japan) |
| 15.2.8. GlaxoSmithKline plc. (U.K.) |
| 15.2.9. Mylan N.V. (U.S.), Tecan Group (Switzerland) |
| 15.2.10. AureoGen Biosciences Inc. (U.S.) |
| 16. Research Methodology |
| 17. Key Assumptions and Acronyms |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
